• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Sickle Cell Groups, Pfizer Work to Bring African-Americans into Clinical Trials


It’s been nearly half a century since the end of Alabama’s Tuskegee experiment, the infamous 40-year study in which the U.S. government intentionally gave 399 syphilis-infected black men useless placebos — like aspirin and mineral supplements — instead of penicillin, which could have cured them.

Yet suspicions still linger, complicating today’s efforts to recruit African-Americans into clinical trials for sickle cell disease (SCD), which disproportionately affects black people.

Pfizer, with the help of the Sickle Cell Disease Association of America, is trying to change that.

The New York-based pharma giant, which is now recruiting for its own clinical trials in sickle cell disease, recently launched oneSCDvoice, a collaborative digital platform aimed at educating and lending emotional support to people with SCD.

https://www.onescdvoice.com/wp-content/uploads/2018/05/SCDPfizer.jpg

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close